SCHEDULE 13G/A: Logos Global Management Reports Zero Beneficial Ownership in NextCure, Inc. via Amended SEC Filing
Beneficial Ownership Report
Logos Global Management LP and its affiliated entities have filed an amended Schedule 13G, disclosing that they no longer hold any beneficial ownership in NextCure, Inc. as of December 31, 2024.
Summary
- Logos Global Management LP, along with its related entities Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, filed an Amendment No. 2 to Schedule 13G.
- The filing reports beneficial ownership of common stock in NextCure, Inc. (CUSIP: 65343E108).
- As of the event date of December 31, 2024, all reporting persons hold 0.00 shares, representing 0% of the class of NextCure, Inc. common stock.
- The reporting persons disclaim beneficial ownership of Common Stock except to the extent of their pecuniary interest therein, and the Global Fund disclaims beneficial ownership as defined in Rule 13d-3 under the Act.
- The filing was made pursuant to Rule 13d-1(b), indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership, reporting 0% ownership. It contains no positive or negative statements about the issuer's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by an institutional investor, indicating a complete divestment or lack of a significant stake in NextCure, Inc. It does not provide insights into broader industry trends or NextCure's operational performance, but rather reflects a specific investment firm's portfolio adjustments.
Stakeholder Impact
- Shareholders: This filing indicates that Logos Global Management and its affiliates no longer hold a significant stake in NextCure, Inc., which might be noted by other institutional investors tracking ownership changes. However, it does not directly impact the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement, indicating the reporting period end. |
| 02/13/2025 | Signing date for Logos Global Management LP. |
| 02/14/2025 | Signing date for Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William. |
Keywords
NextCure Inc., Logos Global Management, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Institutional Ownership, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.